Business
Marker Therapeutics Reports Second Quarter 2021 Operating and Financial Results
Marker continues to enroll patients and activate clinical sites in Phase 2 AML trial following completion of safety lead-in Company's new in-house cGMP
About this update from Marker Therapeutics, Inc.
[{"type":"text","content":"Marker continues to enroll patients and activate clinical sites in Phase 2 AML trial following completion of safety lead-in\n Company's new in-house cGMP manufacturing facility in Houston is fully operational\n\n\nHOUSTON, Aug. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the second quarter ended June 30, 2021. \n\n \n \n \n \n \n \n\n \n\"Marker accomplished a number of strategic goals and clinical milestones this quarter, including completing the safety lead-in portion of our Company-sponsored Phase 2 trial investigating Marker's MultiTAA-specific T cell therapy in post-transplant acute myeloid leukemia, or AML,\" said Peter L. Hoang, President & CEO of Marker Therapeutics. \"We are now enrolling patients as well as activating additional clinical sites in the main portion of the trial. In parallel, we opened a new in-house cGMP manufacturing facility in Houston and recently announced that the facility is fully operational. We look forward to manufacturing study drug at the new facility next quarter, which we expect will yield quality product, reduce manufacturing costs and expand patient access to Marker's MultiTAA-specific T cell therapies.\" \nPROGRAM UPDATES\nIn June 2021, Marker completed the six-patient safety lead-in portion of the Company's Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant AML. The Company continues to enroll patients in the main portion of the trial and activate clinical sites across the U.S. The trial is expected to enroll approximately 120 patients in the adjuvant setting and 40 patients with active disease at approximately 20 clinical sites.BUSINESS UPDATES\nMarker recently announced that the Company's new cGMP manufacturing facility in Houston, TX, located near the George Bush Intercontinental Airport, is fully operational. The facility will manufacture Marker's MultiTAA-specific T cell products for the Company's Phase 2 AML trial as well as future hematological and solid tumor trials, in addition to producing the potential commercial supply of any app...